Skip to content

Travere Therapeutic

US · TVTX #2056 by market cap Listed 1970
53.44 -2.54 -4.54%
Live - 5344 symbols - heartbeat 569s ago · 2026-10-08 07:24
Pre-market 53.30 -0.26%
After-hours 53.44 0.00%
Market cap
5.04B
P/E (TTM)
-116.17
P/B
205.54
EPS
-0.29
Reader sentiment Are you bullish or bearish on TVTX?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
  • Total institutional ownership fell 0.5 percentage points.

Institutional ownership

Held by institutions
115.34% -0.50pp
Institutions
394 +2
As of
2026/Q3 vs. prior period

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Holder types

Mutual Fund76.58%
Hedge Fund20.98%
Public Company6.47%
VC/PE Fund5.80%
Private Company3.95%
Individual/Insider1.10%
Insurance Company0.81%
Government Pension Fund0.68%

Top holders as of 2026-06-30

Janus Henderson Group plc 12.01% · 11.32M sh
BlackRock 8.51% · 8.02M sh
FMR 6.51% · 6.14M sh
Vanguard Capital Management, LLC 5.06% · 4.77M sh
State Street Global Advisors 4.52% · 4.26M sh
Bank of America Corporation 4.17% · 3.93M sh
Perceptive Advisors LLC 3.98% · 3.75M sh
Macquarie Investment Management Business Trust 2.98% · 2.81M sh
Emerald Advisers, LLC 2.79% · 2.63M sh
Adage Capital Management, L.P. 2.73% · 2.57M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 18 buys · 32 sells

NameRoleStake
Eric Dube Chief Executive Officer 0.16%
Elizabeth Reed Senior Vice President 0.11%
Jula Inrig Chief Medical Officer 0.11%
Jeffrey Meckler Independent Director 0.10%
Christopher Cline Chief Financial Officer 0.09%
William Rote Senior VP and Head of Research & Development 0.07%
Gary Lyons Independent Chairperson 0.07%
Peter Heerma Chief Commercial Officer 0.07%
Timothy Coughlin Independent Director 0.06%
Sandra Calvin SVP, Corporate Controller & Chief Accounting Officer 0.04%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-16 Eric Dube Chief Executive Officer Derivative Exercise and Sale -400,000 $23.34–65.31
2026-09-16 Eric Dube Chief Executive Officer Intent to Sell (Form 144) -108,493 $63.48
2026-09-16 Peter Heerma Chief Commercial Officer Derivative Exercise and Sale -258,189 $8.93–65.07
2026-09-16 Peter Heerma Chief Commercial Officer Intent to Sell (Form 144) -8,282 $63.48
2026-09-15 William Rote Senior VP and Head of Research & Development Intent to Sell (Form 144) -112,850 $62.51
2026-09-15 Eric Dube Chief Executive Officer Intent to Sell (Form 144) -195,841 $62.51
2026-09-15 Peter Heerma Chief Commercial Officer Intent to Sell (Form 144) -172,717 $62.51
2026-09-14 Elizabeth Reed Senior Vice President Derivative Exercise and Sale -37,500 $15.46–65.31
2026-09-14 William Rote Senior VP and Head of Research & Development Intent to Sell (Form 144) -96,198 $65.79
2026-09-14 Christopher Cline Chief Financial Officer Automatic Disposition -30,508 $62.00–65.31
2026-09-14 Christopher Cline Chief Financial Officer Derivative Exercise and Sale -20,000 $17.44–62.00
2026-09-14 Eric Dube Chief Executive Officer Intent to Sell (Form 144) -95,666 $65.79
2026-09-14 Peter Heerma Chief Commercial Officer Automatic Disposition -25,000 $62.59–65.31
2026-09-14 Sandra Calvin SVP, Corporate Controller & Chief Accounting Officer Derivative Exercise and Sale -5,375 $20.46–63.66
2026-09-14 Jula Inrig Chief Medical Officer Automatic Disposition -12,279 $62.62–65.31
2026-09-14 Jula Inrig Chief Medical Officer Derivative Exercise and Sale -32,395 $8.93–62.62
2026-09-09 Jeffrey Meckler Independent Director Derivative Exercise and Sale -20,000 $17.44–68.09
2026-09-01 Christopher Cline Chief Financial Officer Open Market Disposition -642 $66.37
2026-08-17 Gary Lyons Independent Chairperson Derivative Exercise and Sale -10,000 $17.44–64.16
2026-08-17 Gary Lyons Independent Chairperson Intent to Sell (Form 144) -5,000 $63.53

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-10-08 07:24:39 · For reference only, not investment advice and not tailored to your situation.